



Metabolic Diseases Regulators

Guest Editor:

Dr. Mariana Georgeta Roșca

Department of Foundational
Sciences, Central Michigan
University College of Medicine,
Mount Pleasant, MI 48858, USA

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editor

Dear Colleagues,

Metabolic syndrome is a group of metabolic abnormalities centered around excessive visceral adiposity that involves diseases in target organs, mainly cardiovascular system, skeletal muscle, pancreas and liver. Diseases associated with metabolic syndrome are associated with a high level of morbidity and mortality. Treating organ diseases that are induced by metabolic syndrome is cumbersome. Therefore, identifying common pathogenic mechanisms and specific factors is the focus of multidisciplinary approaches, the aim of which is to translate this knowledge into prevention and therapy. This Special Issue is focused on unfolding the role of novel regulators that are involved in the development of the metabolic syndrome and related organ diseases. The scope is to reveal potential therapeutic targets that are common for metabolic diseases.

Dr. Mariana Georgeta Roșca
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)